Download our info sheet to learn more about our capabilities.
Watch Our Latest Webinar
Approaching the end of your Phase II milestone & gearing up for phase III and beyond? For most drug programs, a key step for inclusion in a successful global regulatory filing is to conduct a 14C human ADME study. In our latest webinar, Iain Shaw, Sr. Director of 14C Drug Development at Quotient Sciences, along with a panel of experts from our drug development, radiosynthesis and clinical pharmacology teams discuss efficient ADME study design, common challenges that can occur and mistakes to avoid, and how human ADME studies can improve decision making at critical drug development milestones.